Predictive value of C-reactive protein after drug-eluting stent implantation

Rocco Antonio Montone, Giuseppe Ferrante, Marco Bac, Giampaolo Niccoli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

During the last few decades, with the evolution of techniques and materials and the increasing experience of operators, percutaneous coronary interventions (PCI) have become an equally efficient alternative to coronary artery bypass grafts for the treatment of most coronary stenoses. Bare-metal stent implantation represented a major step forward, compared with plain old balloon angioplasty (POBA), by improving the immediate angiographic success. However, the incidence of in-stent restenosis (ISR) remained unacceptably high. Development of the drug-eluting stent (DES) significantly improved the outcome of PCI by dramatically abating the rate of ISR and reducing the incidence of target lesion revascularization. However, ISR has not been eliminated and the persistence of metal vessel scaffolding also raises concern regarding the occurrence of late or very late stent thrombosis. POBA and stent implantation have been shown to induce a local and systemic inflammatory response, whose magnitude is associated with worse clinical outcome, and they increase the risk of ISR. C-reactive protein, a marker of systemic inflammation, has been demonstrated to predict clinical and angiographic outcome after POBA or bare-metal stent implantation. However, conflicting data regarding the prognostic value of C-reactive protein following DES implantation are available. In this paper, we review the literature regarding the clinical and pathophysiological association between inflammation and prognosis after DES implantation and suggest some possible therapeutic approaches to reduce inflammatory burden with the aim to improve clinical and angiographic outcome after PCI.

Original languageEnglish
Pages (from-to)167-179
Number of pages13
JournalFuture Cardiology
Volume6
Issue number2
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Drug-Eluting Stents
C-Reactive Protein
Stents
Balloon Angioplasty
Percutaneous Coronary Intervention
Metals
Inflammation
Coronary Stenosis
Incidence
Coronary Artery Bypass
Thrombosis
Transplants
Therapeutics

Keywords

  • C-reactive protein
  • Drug-eluting stent
  • In-stent restenosis
  • Inflammation
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Predictive value of C-reactive protein after drug-eluting stent implantation. / Montone, Rocco Antonio; Ferrante, Giuseppe; Bac, Marco; Niccoli, Giampaolo.

In: Future Cardiology, Vol. 6, No. 2, 03.2010, p. 167-179.

Research output: Contribution to journalArticle

Montone, Rocco Antonio ; Ferrante, Giuseppe ; Bac, Marco ; Niccoli, Giampaolo. / Predictive value of C-reactive protein after drug-eluting stent implantation. In: Future Cardiology. 2010 ; Vol. 6, No. 2. pp. 167-179.
@article{85ef2c57572e4eddb3919939739a7b8e,
title = "Predictive value of C-reactive protein after drug-eluting stent implantation",
abstract = "During the last few decades, with the evolution of techniques and materials and the increasing experience of operators, percutaneous coronary interventions (PCI) have become an equally efficient alternative to coronary artery bypass grafts for the treatment of most coronary stenoses. Bare-metal stent implantation represented a major step forward, compared with plain old balloon angioplasty (POBA), by improving the immediate angiographic success. However, the incidence of in-stent restenosis (ISR) remained unacceptably high. Development of the drug-eluting stent (DES) significantly improved the outcome of PCI by dramatically abating the rate of ISR and reducing the incidence of target lesion revascularization. However, ISR has not been eliminated and the persistence of metal vessel scaffolding also raises concern regarding the occurrence of late or very late stent thrombosis. POBA and stent implantation have been shown to induce a local and systemic inflammatory response, whose magnitude is associated with worse clinical outcome, and they increase the risk of ISR. C-reactive protein, a marker of systemic inflammation, has been demonstrated to predict clinical and angiographic outcome after POBA or bare-metal stent implantation. However, conflicting data regarding the prognostic value of C-reactive protein following DES implantation are available. In this paper, we review the literature regarding the clinical and pathophysiological association between inflammation and prognosis after DES implantation and suggest some possible therapeutic approaches to reduce inflammatory burden with the aim to improve clinical and angiographic outcome after PCI.",
keywords = "C-reactive protein, Drug-eluting stent, In-stent restenosis, Inflammation, Percutaneous coronary intervention",
author = "Montone, {Rocco Antonio} and Giuseppe Ferrante and Marco Bac and Giampaolo Niccoli",
year = "2010",
month = "3",
doi = "10.2217/fca.09.159",
language = "English",
volume = "6",
pages = "167--179",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Predictive value of C-reactive protein after drug-eluting stent implantation

AU - Montone, Rocco Antonio

AU - Ferrante, Giuseppe

AU - Bac, Marco

AU - Niccoli, Giampaolo

PY - 2010/3

Y1 - 2010/3

N2 - During the last few decades, with the evolution of techniques and materials and the increasing experience of operators, percutaneous coronary interventions (PCI) have become an equally efficient alternative to coronary artery bypass grafts for the treatment of most coronary stenoses. Bare-metal stent implantation represented a major step forward, compared with plain old balloon angioplasty (POBA), by improving the immediate angiographic success. However, the incidence of in-stent restenosis (ISR) remained unacceptably high. Development of the drug-eluting stent (DES) significantly improved the outcome of PCI by dramatically abating the rate of ISR and reducing the incidence of target lesion revascularization. However, ISR has not been eliminated and the persistence of metal vessel scaffolding also raises concern regarding the occurrence of late or very late stent thrombosis. POBA and stent implantation have been shown to induce a local and systemic inflammatory response, whose magnitude is associated with worse clinical outcome, and they increase the risk of ISR. C-reactive protein, a marker of systemic inflammation, has been demonstrated to predict clinical and angiographic outcome after POBA or bare-metal stent implantation. However, conflicting data regarding the prognostic value of C-reactive protein following DES implantation are available. In this paper, we review the literature regarding the clinical and pathophysiological association between inflammation and prognosis after DES implantation and suggest some possible therapeutic approaches to reduce inflammatory burden with the aim to improve clinical and angiographic outcome after PCI.

AB - During the last few decades, with the evolution of techniques and materials and the increasing experience of operators, percutaneous coronary interventions (PCI) have become an equally efficient alternative to coronary artery bypass grafts for the treatment of most coronary stenoses. Bare-metal stent implantation represented a major step forward, compared with plain old balloon angioplasty (POBA), by improving the immediate angiographic success. However, the incidence of in-stent restenosis (ISR) remained unacceptably high. Development of the drug-eluting stent (DES) significantly improved the outcome of PCI by dramatically abating the rate of ISR and reducing the incidence of target lesion revascularization. However, ISR has not been eliminated and the persistence of metal vessel scaffolding also raises concern regarding the occurrence of late or very late stent thrombosis. POBA and stent implantation have been shown to induce a local and systemic inflammatory response, whose magnitude is associated with worse clinical outcome, and they increase the risk of ISR. C-reactive protein, a marker of systemic inflammation, has been demonstrated to predict clinical and angiographic outcome after POBA or bare-metal stent implantation. However, conflicting data regarding the prognostic value of C-reactive protein following DES implantation are available. In this paper, we review the literature regarding the clinical and pathophysiological association between inflammation and prognosis after DES implantation and suggest some possible therapeutic approaches to reduce inflammatory burden with the aim to improve clinical and angiographic outcome after PCI.

KW - C-reactive protein

KW - Drug-eluting stent

KW - In-stent restenosis

KW - Inflammation

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=77949602513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949602513&partnerID=8YFLogxK

U2 - 10.2217/fca.09.159

DO - 10.2217/fca.09.159

M3 - Article

VL - 6

SP - 167

EP - 179

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -